Ikena Oncology (formerly Kyn Therapeutics) is a biotechnology company that discovers and develops biomarker-driven therapies for cancer treatment. It develops programs across distinct molecular targets and biologic pathways modulating both the immune system and the tumor.
|HQ||Boston, MA, US||Map|
Revenue (Q2, 2021)
Net income (Q2, 2021)
EBIT (Q2, 2021)
Market capitalization (23-Sept-2021)
Closing stock price (23-Sept-2021)
Ikena Oncology has 1.03k Twitter Followers. The number of followers has increased 0.9% month over month and increased 5.9% quarter over quarter
Tweets last 30 days
Avg. likes per Tweet
Tweets with engagement
When was Ikena Oncology founded?
Ikena Oncology was founded in 2016.
Who are Ikena Oncology key executives?
Ikena Oncology's key executives are Mark Manfredi, Douglas R. Carlson and Jeffrey Ecsedy.
How many employees does Ikena Oncology have?
Ikena Oncology has 50 employees.
Who are Ikena Oncology competitors?
Competitors of Ikena Oncology include SystImmune, WindMIL Therapeutics and Century Therapeutics.
Where is Ikena Oncology headquarters?
Ikena Oncology headquarters is located at 645 Summer St #101, Boston.
Where are Ikena Oncology offices?
Ikena Oncology has an office in Boston.
How many offices does Ikena Oncology have?
Ikena Oncology has 1 office.
Receive alerts for 300+ data fields across thousands of companies